A recent study from Stanford Medicine has identified genetic variants linked to a phenomenon termed GLP-1 resistance, which may explain why approximately 10% of individuals do not respond effectively to GLP-1 receptor agonists like Ozempic and Wegovy. This resistance occurs despite these individuals having elevated levels of the hormone GLP-1, which is crucial for regulating blood sugar and appetite. The research, involving a decade of experiments in both humans and mice, highlights the need for a deeper understanding of the genetic factors influencing drug efficacy in diabetes and obesity treatment.

The study focused on variants affecting the enzyme PAM (peptidyl-glycine alpha-amidating monooxygenase), which is essential for the activation of various hormones, including GLP-1. Notably, individuals with the p.S539W and p.D563G PAM variants exhibited significantly lower responses to GLP-1 drugs, with only 11.5% of those with the p.S539W variant achieving target HbA1c levels after six months of treatment, compared to 25% of those without the variant. These findings suggest that understanding an individual’s genetic makeup could enhance the precision of diabetes treatment, allowing for more tailored therapeutic approaches.

The implications of this research are profound for the field of precision medicine. Identifying genetic markers that predict GLP-1 resistance could streamline drug development timelines and improve patient outcomes by ensuring that individuals receive the most effective treatments from the outset. As the study indicates, while the biological mechanisms underlying GLP-1 resistance remain elusive, advancing our understanding of these genetic factors could lead to the development of new strategies to overcome resistance, potentially through modified drug formulations or novel therapeutic agents.

Source: sciencedaily.com